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Netherton syndrome is a severe autosomal recessive
skin disorder characterized by congenital erythro-
derma, a speci®c hair-shaft abnormality, and atopic
manifestations with high IgE levels. Recently, we
identi®ed SPINK5, which encodes the serine protease
inhibitor Kazal-type 5 protein (LEKTI), as the
defective gene in Netherton syndrome. Here we des-
cribe the intron±exon organization of the gene and
characterize the SPINK5 mutations in patients from
21 families of different geographic origin, using
denaturing high performance liquid chromatography
and direct sequencing. We identi®ed 18 mutations,
of which 13 were novel and seven (39%) were recur-
rent. The majority of the mutations were clustered
between exons 1±8 and exons 21±26. They comprised
four nonsense mutations (22%), eight frameshift
insertions or deletions (44%), and six splice-site
defects (33%). All mutations predict the formation of
premature termination codons. Northern blot analy-
sis showed variable reduction of SPINK5 mutant
transcript levels, suggesting variable ef®ciency of
nonsense-mediated mRNA decay. Seven patients
were homozygotes, eight were compound hetero-
zygotes, and ®ve were heterozygotes with only one
identi®able SPINK5 mutation. Five mutations, one
of which resulted in perinatal lethal disease in three
families, were associated with certain ethnic groups.
We also describe 45 intragenic polymorphisms in the
patients studied. The clinical features of erythro-
derma, trichorrhexis invaginata, and atopic manifest-
ations were present in the majority of affected
individuals and ichthyosis linearis circum¯exa was
seen in 12 out of 24 patients. Interfamilial and
intrafamilial variation in disease severity was
observed, with no clear correlation between muta-
tions and phenotype, suggesting that the degree of
severity may be affected by other factors. Key words:
atopy/epidermal differentiation/erythroderma/ichthyosis/
serine protease inhibitor. J Invest Dermatol 118:352±361,
2001
N
etherton syndrome (NS, MIM 256500) is a severe
autosomal recessive skin disorder characterized by
congenital ichthyosis, a speci®c hair shaft abnorm-
ality [trichorrhexis invaginata (TI) or ``bamboo
hair''], and atopic manifestations (ComeÁl, 1949;
Netherton, 1958; Traupe, 1989; Plantin et al, 1991). It was ®rst
described by ComeÁl in 1949 (ComeÁl, 1949) and Netherton in 1958
(Netherton, 1958). Incidence has been estimated at 1 in 200,000,
but a recent study reports that NS could account for up to 18% of
congenital erythodermas (Pruszkowski et al, 2000). Generalized
scaly erythroderma is apparent at or soon after birth and usually
persists. Ichthyosis linearis circum¯exa, which typically consists of
serpiginous patches bordered by double-edged scales (ComeÁl, 1949;
Altman and Stroud, 1969; Hausser and Anton-Lamprecht, 1996),
develops in some patients during the ®rst years of life. Scalp hair is
sparse and brittle with a characteristic ``bamboo'' shape under light
microscopic examination due to invagination of the distal part of
the hair shaft to its proximal part. TI expression may not affect all
hair, thus making the diagnosis of NS dif®cult to establish at an
early age (Stevanovic, 1969). Eyelashes and eyebrows may be
affected. Patients also exhibit atopic manifestations including
eczema-like rashes, atopic dermatitis, pruritus, hay fever, angio-
edema, urticaria, high levels of immunoglobulin E in the serum,
and hypereosinophilia (Judge et al, 1994; Smith et al, 1995;
Rudikoff and Lebwohl, 1998). Speci®c IgE antibodies to a range of
airborne and food allergens are frequent in NS patients, but studies
on immune function showed no consistent or signi®cant
abnormalities (Judge et al, 1994). Histologic and ultrastructural
studies of patients' skin sections reveal incomplete keratinization of
the epidermis and defective corni®cation, with dermal lymphocytic
in®ltrate (Hausser and Anton-Lamprecht, 1996).
NS is a complex disease and life-threatening complications are
frequent during the neonatal period, including hypernatraemic
dehydration, hypothermia, extreme weight loss, bronchopneumo-
nia, and sepsis (Jones et al, 1986). During childhood, failure to
thrive is common as a result of malnutrition, metabolic disorders,
chronic erythroderma, persistent cutaneous infections, or entero-
pathy (Jones et al, 1986; Judge et al, 1994).
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Using a candidate positional cloning approach, we recently
localized and subsequently identi®ed SPINK5 (serine protease
inhibitor, Kazal-type 5) as the defective gene in NS (Chavanas et al,
2000a; 2000b). The gene spans a region of 61 kb and is composed
of 33 exons. It encodes a protein of 1064 amino acids organized in
15 domains (D1±D15), two of which (D2 and D15) perfectly
match the Kazal-type putative serine protease inhibitory pattern C-
(X)n-C-(X)7-C-(X)10-C-(X)2/3-C-(X)m-C, where the cysteine
residues C are involved in three disul®de bonds in 1±5, 2±4, and
3±6 pattern. The protein encoded by SPINK5 is highly expressed
in thymus and mucous epithelia, and thereby termed LEKTI for
lympho-epithelial Kazal-type related inhibitor (MaÈgert et al, 1999).
LEKTI was found to be the precursor of at least two proteolytic
fragments (D1 and D6) of which one (D6) was demonstrated to
exert an inhibitory effect on trypsin in vitro. This ®nding suggested
that LEKTI could play a role in anti-in¯ammatory and/or
antimicrobial protection of mucous epithelia. As the protein is
also highly expressed in cultured epidermal keratinocytes (Chavanas
et al, 2000b), it is possible that LEKTI could have a similar function
in the epidermis (MaÈgert et al, 1999).
Serine proteases and their inhibitors play a pivotal role in a wide
variety of immune and in¯ammatory processes, including T and B
cell differentiation, activation of cytokines and complement, and
recruitment of in¯ammatory cells (Roberts et al, 1995). Possible
targets for LEKTI would include the mast cell tryptase, a key
mediator in immediate hypersensitivity reaction, which activates
protease-activated receptors present on the cell surface of human
keratinocytes (Schechter et al, 1998). In addition, the recent
identi®cation of a thymus-speci®c serine protease (Bowlus et al,
1999), together with the strong expression of LEKTI in the thymus
(MaÈgert et al, 1999), supports a role for LEKTI in T cell maturation,
selection, and/or antigen processing. LEKTI would thus be a
putative downregulator of epithelial and mucosal in¯ammation,
whose defective expression would result in unbalanced Th2
response and enhanced in¯ammation in target tissues.
Interestingly, several allergens including the major house dust-
mite and pollen have been identi®ed as serine proteases with IgE
binding capacity (Bagarozzi et al, 1998; Kawamoto et al, 1999).
Such moieties represent possible targets for LEKTI, the multi-
domains organization of which could enhance its allergen-trapping
capacity.
Defective keratinization in NS also suggests a role for LEKTI in
epidermal differentiation. Several serine proteases, including the
stratum corneum chymotryptic enzyme and the stratum corneum
tryptic enzyme, are thought to be involved in desquamation
through the proteolysis of intercellular adhesion molecules
(Ekholm et al, 2000). Premature secretion of lamellar body contents
and disturbance in the formation of the intercellular lipid layers
have been suggested as distinctive features of NS (Fartasch et al,
1999). This raises the possibility that lack of regulation of target
serine proteases could lead to impaired organization of lamellar-
body-derived lipid structures in the stratum corneum.
Alternatively, LEKTI could regulate proteolysis of membrane-
bound receptors involved in keratinocyte growth and differenti-
ation (Derian et al, 1997; Dery et al, 1998). As a result of loss of
LEKTI function, defective epidermal barrier would facilitate
exposure to allergens and the development of IgE response.
We initially described 11 SPINK5 mutations in 13 families with
NS. All of these mutations created premature termination codons
(PTCs) of translation, predicting marked instability of mutated
SPINK5 transcripts and loss of expression of LEKTI (Chavanas et
al, 2000b). In the recent study by Sprecher et al almost half of the 17
SPINK5 mutations were located between exons 2 and 8 (Sprecher
et al, 2001). To better understand the molecular basis of the disease,
we screened SPINK5 for mutations in 21 unrelated families, using
denaturing high performance liquid chromatography (DHPLC).
We report the characterization of 18 distinct mutations of which 13
are novel, and we compare these results with expression of the
disease. We also describe SPINK5 genomic organization and 45
intragenic polymorphisms identi®ed during the study.
MATERIALS AND METHODS
SPINK5 genomic structure In silico screening of the high-
throughput genomic sequence (htgs) database with the LEKTI cDNA
sequence identi®ed the sequence generated from BAC 94F21 as a
template containing SPINK5. The position and size of introns 1±7, 9,
11±15, and 17±32 of SPINK5 were then characterized by BLAST
analysis of the LEKTI cDNA sequence against this sequence. Intronic
boundaries of exons 8, 10, 16, and 33 were characterized by long-range
polymerase chain reaction (PCR) using control human genomic DNA as
a template and speci®c exonic or intronic primers, according to the
supplier's recommendations (Expand Long Template PCR System,
Roche). PCR products were subcloned into the pCRII-TOPO vector
(TOPO TA Cloning Kit, Invitrogen), and individual clones were
sequenced using the dye-terminator chemistry (Applied Biosystems).
Patients We studied 26 patients affected with NS from 21 families not
known to be related. Five families had two affected children (families 12,
13, 15, 19, and 21). Parental consanguinity was known in seven families
(families 10, 13, 14, and 16±19). Families originated from Europe
(England, Ireland, Scotland, France, Italy, Kosovo), the Middle East
(Turkey), Central Asia (Pakistan), and Asia (China, Japan). All patients
were assessed by at least one of the authors. The age of the patients
ranged from newborn to 38 y at the time of the study. Diagnosis of NS
was based on family history and clinical examination according to the
following parameters: scaly erythroderma in the ®rst days of life, TI,
ichthyosis linearis circum¯exa, and atopic manifestations (Table I).
Extra-cutaneous involvement was also recorded. All patients except
patient 13.1 exhibited scaly erythroderma and all patients except patient
15.1 were noted to have TI. In 12 patients, scaly erythroderma
progressed into ichthyosis linearis circum¯exa during the ®rst years of
infancy. All living patients had atopic manifestations with high IgE levels.
The course of the disease was severe in several families. The affected
child in families 17 and 18 died at age 11 d and 6 d, respectively, as a
result of dehydration and candida sepsis. Family 19 gave a history of
having another affected child who died in infancy from erythroderma.
Failure to thrive in infancy, often profound, was seen in 18 patients and
required intensive nutritional support. In 12 patients, severe
hypernatraemic dehydration necessitated intense medical care. Cutaneous
recurrent infections were found in 18 patients. Individual patient details
are shown in Table I. Routine hematologic and biochemical
investigations re¯ected the current medical condition when the patient
was acutely unwell due to a disease-related complication, or were
subnormal when the condition was stable. Serum IgG, IgM, and IgA
levels were normal. Total IgE levels were raised in all patients with a
range of 400±8000 i.u. per ml (normal < 180 i.u. per ml). In patient 18,
mutation screening was performed from the parents' DNA only, as a
blood sample from the patient was unavailable. Patient and ethical
committee approvals were obtained for this study.
PCR ampli®cation Genomic DNA was extracted from peripheral
blood leukocytes using standard methods (Sambrook et al, 1989). PCR
ampli®cation of SPINK5 was performed with 35 pairs of oligonucleotide
primers spanning all 33 exons, ¯anking splice sites, and the ®rst 490 bp
of the proximal promoter region (Table III). PCR conditions consisted
of 95°C for 10 min followed by 12 touch-down cycles (94°C for 30 s,
annealing temperature ranging from 58°C to 62°C with an increment of
±0.5°C per cycle, for 30 s, and 72°C for 30 s) and 30 cycles of (94°C
for 30 s, annealing temperature ranging from 52°C to 56°C for 30 s, and
72°C for 30 s) in an MJ Research PTC-100 thermal cycler. All PCRs
were performed in the presence of 2.5 mM MgCl2, 1 3 PCR buffer II
(Perkin Elmer), 200 mM of each dNTP, 200 nM of each (forward and
reverse) primer, and a 9:1 combination of Taq Gold (Perkin Elmer) and
Pfu Turbo polymerases (Stratagene). All PCR products were run on 2%
agarose gels to search for possible large insertions or deletions before
analysis by DHPLC.
To assess for the presence of mutation(s) or polymorphism(s) altering
or generating restriction enzyme sites, ampli®ed genomic DNA was
cleaved with the appropriate restriction enzyme according to the manu-
facturer's recommendations (New England Biolabs and Life
Technologies) and analyzed either on 3% agarose or 6% polyacrylamide
gel electrophoresis.
DHPLC and sequence analysis After PCR ampli®cation, patient and
control DNA were mixed in a 3:1 ratio (vol/vol), denatured at 95°C for
4 min, and subjected to a touch-down program of 42 cycles (±1.6°C per
cycle for 1 min) to induce formation of heteroduplexes. Samples were
then separately injected for 6.8 min with a temperature gradient
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Table I. Clinical features of NS patients
Associated features
Familya
Diagnostic parametersc Failure to
thrive
in infancy
Recurrent
infections
Hypernatremic
dehydration
Persistent
pruritus
Growth
retardation EnteropathyAgeb (y) SE TI ILC Atopic manifestations
1 8 + + + E, AO, H-IgE + + + ± + +
2 37 + + + E, AO, Hf, H-IgE, U ± + ± + + ±
3 7 + + + E, Hf, H-IgE, U + + ± ± + ±
4 20 + + + E, Hf, H-IgE, He, A ± ± ± + ± ±
5 7 + + + AO, H-IgE, U + + ± + ± ±
6 38 + + + E, AO, Hf, H-IgE, U + + ± + + ±
7 4 + + ± E, H-IgE ± + + + ± ±
8 8 + + ± E, Hf, H-IgE + + ± + + +
9 12 + + ± E, AO, AD, Hf, H-IgE, He, U + + + + + +
10 8 + + ± E, H-IgE, He + ± ± + + ±
11 10 + + + E, A, Hf, H-IgE, He + ± + + + ±
12.1 29 + + ± AD, A, H-IgE + + + + + ±
12.2 15 + + ± AD, H-IgE ± + ± + ± ±
13.1 8 ± + + E, H-IgE ± ± ± + ± ±
13.2 5 + + + E, H-IgE, He, A + ± ± + + ±
14 2 + + + E, H-IgE + + + + + +
15.1 14 + + + E, Hf, AO, H-IgE + + + + + +
15.2 6 + ± ± E, Hf, AO, H-IgE, A + + + + + +
16 5 + + ± E, H-IgE, Hf + + + ± + +
17 ² + ND ND ±
18 ² + + ± E, AO, H-IgE, A + + ± ± ± ±
19.1 ² + ND ND
19.2 11 + + + AD, H-IgE, He + + + ± + ±
20 4 + + ± E, H-IgE ± + + + ± ±
21.1 4 + + ± E, H-IgE + + + + ± ±
21.2 3 + + ± E, H-IgE + ± ± + ± ±
aSome families have two affected children (families 12, 13, 15, 19, and 21).
b²indicates that the patient died during the neonatal period as a result of dehydration or sepsis.
cSE, scaly erythroderma at birth; TI, trichorrhexis invaginata; ILC, ichthyosis linearis circum¯exa; E, eczema-like rashes; AD, atopic dermatitis; AO, angio-edema; Hf, hay fever; H-IgE, hyper immunoglobulin E; He, hypereosi-
nophilia; U, urticaria; A, asthma; ND, not determined.
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previously calculated using the 3.4WAVEMaker program
(Transgenomic). Samples showing abnormal DHPLC running pro®le
were puri®ed using Qiaquick PCR puri®cation columns (Qiagen) and
sequenced using the Big Dye terminator cycle sequencing kit and an
ABI377 automated sequencer (Applied Biosystems). All PCR products
were sequenced in both forward and reverse orientations.
RNA extraction, reverse transcription PCR (RT-PCR), and
northern blot Total RNA was extracted from patients' keratinocytes
cultured in vitro using Trizol (Life Technologies), according to the
manufacturer's recommendations. cDNA was generated from total RNA
by reverse transcription using random hexamers and Superscript Reverse
Transcriptase (Life Technologies). SPINK5 exonic primers encompassing
the exons ¯anking the mutations were used for PCR ampli®cation of
the cDNA (same conditions as described above). RT-PCR products
were run on a 2% agarose gel. Bands of abnormal size compared to the
control were extracted from the gel and directly sequenced with the
same primers used for RT-PCR ampli®cation. Northern blot analysis of
total RNA extracts was performed using standard methods (Sambrook
et al, 1989).
Genotype analysis Two polymorphic microsatellite markers (GT)17
(EMBL accession number AJ304416) and (CA)20 (EMBL accession
number AJ304417), respectively, located 1.7 and 14 kb upstream of the
SPINK5 ATG codon, were identi®ed by analysing the sequence of the
5¢ untranslated region of SPINK5 from BAC 94F21. These markers
were used to genotype individuals from families with recurrent mutations
(1±9, 11, 12, 15±19, and 21). Genotyping was performed on an ABI377
automated DNA sequencer, using the following pairs of primers for
PCR ampli®cation: (GT)17-L, 5¢-ACTATTCCATTGGAAAGGAG-3¢;
(GT)17-R, 5¢-GGGTGTGTGAGTTGAGATGG-3¢; (CA)20-L, 5¢-GAA-
CAATTTGATAATGGTGTG-3¢; (CA)20-R, 5¢-AAGAATCCTAAGC-
ACAATGTG-3¢. (GT)17-R and (CA)20-R primers were labeled with,
respectively, 6-FAM (6-carboxy¯uorescein) and HEX (4,7,2¢,4¢,5¢,7-
hexachloro-6-carboxy¯uorescein). PCR conditions were as described
above, with an annealing temperature of 55°C.
RESULTS
Genomic structure The intron±exon organization of SPINK5
was determined by a combination of electronic search and
sequencing of long PCR products from human BAC 94F21
containing SPINK5 and genomic DNA. SPINK5 is encoded by 33
exons and spans a region of 61 kb. Table III lists the size and
starting position of each exon, together with ¯anking intronic
Table II. Characteristics of SPINK5 mutations identi®ed in 21 NS patientsa
Patient Origin Mutation Nucleotide change Consequence Location Veri®cation method
1 England 1036insG(A)4 G(A)4AGG®G(A)4G(A)4AGG frameshift (PTC + 31aa) exon 12 sequencing
R371X 1111C®T nonsense (PTC) exon 13 ± TaqI
2 England R371X 1111C®T nonsense (PTC) exon 13 ± TaqI
81 + 2T®A CAGgtt®CAGgat altered splicing intron 2 sequencing
3 North Ireland ?
2468delA (A)10G®(A)9G frameshift (PTC + 26aa) exon 26 sequencing
4 Scotland 2468delA (A)10G®(A)9G frameshift (PTC + 26aa) exon 26 sequencing
?
5 England 2264insA (A)6T®(A)7T frameshift (PTC + 3aa) exon 24 sequencing
R790X* 2368C®T nonsense (PTC) exon 25 ± TaqI
6 England ?
2240 + 1G®A ATTgt®ATTat altered splicing (PTC + 8aa) intron 23 sequencing
7 France 2240 + 1G®A ATTgt®ATTat altered splicing (PTC + 8aa) intron 23 sequencing
81 + 5G®A CAGgttag®CAGgttaa altered splicing (PTC + 8aa) intron 2 + MseI
8 France 1608±1G®A AgCAA®aaCAA altered splicing intron 17 sequencing
2468delA (A)10G®(A)9G frameshift (PTC + 26aa) exon 26 sequencing
9 France 238insG* GGGC®GGGGC frameshift (PTC + 16aa) exon 4 + NlaIV
?
10 Italy 1888±1G®A* agGAG®aaGAG altered splicing (PTC + 85aa) intron 20 + MseI
1888±1G®A* agGAG®aaGAG altered splicing (PTC + 85aa) intron 20 + MseI
11 Italy 2041delAG GAGGA®GGA frameshift (PTC + 26aa) exon 22 sequencing
R371X 1111C®T nonsense (PTC) exon 13 ± TaqI
12 Italy 238insG* GGGC® GGGGC frameshift (PTC + 16aa) exon 4 + NlaIV
R217X 649C®T nonsense (PTC) exon 8 ± TaqI
13 Pakistan R210X 628C®T nonsense (PTC) exon 8 sequencing
R210X 628C®T nonsense (PTC) exon 8 sequencing
14 Pakistan 2468insA* (A)10G®(A)11G frameshift (PTC + 6aa) exon 26 sequencing
2468insA* (A)10G®(A)11G frameshift (PTC + 6aa) exon 26 sequencing
15 Kosovo 81 + 2T®A CAGgtt®CAGgat altered splicing intron 2 sequencing
153delT* (T)6C®(T)5C frameshift (PTC + 6aa) exon 3 + XmnI
16 Turkey 153delT* (T)6C®(T)5C frameshift (PTC + 6aa) exon 3 + XmnI
153delT* (T)6C®(T)5C frameshift (PTC + 6aa) exon 3 + XmnI
17 Turkey 153delT* (T)6C®(T)5C frameshift (PTC + 6aa) exon 3 + XmnI
153delT* (T)6C®(T)5C frameshift (PTC + 6aa) exon 3 + XmnI
18 Turkey 153delT* (T)6C®(T)5C frameshift (PTC + 6aa) exon 3 + XmnI
153delT* (T)6C®(T)5C frameshift (PTC + 6aa) exon 3 + XmnI
19 Turkey 153delT* (T)6C®(T)5C frameshift (PTC + 6aa) exon 3 + XmnI
153delT* (T)6C®(T)5C frameshift (PTC + 6aa) exon 3 + XmnI
20 China 56G®A AGGgt®AGAgt altered splicing exon 1 + HphI
?
21 Japan R790X* 2368C®T nonsense (PTC) exon 25 ± TaqI
377delAT ATATG®ATG frameshift (PTC + 7aa) exon 5 ± NdeI
aAmino acid and nucleotide numbering refers to the cDNA sequence, with nucleotide position 1 assigned to the ®rst nucleotide of the ATG initiation codon in exon 1.
Bases in exons are noted by upper case letters and bases in introns by lower case letters. Altered bases involved in frameshift and splice-site mutations are underlined.
(PTC + naa) indicates that the PTC is located n amino acids downstream of the mutation. ? indicates that no mutation was identi®ed after sequencing the entire coding
and proximal promoter regions of the gene. ± and + symbols represent, respectively, the disruption or the generation of an enzymatic restriction site. An asterisk indicates
that the mutation has been reported previously in different NS patients (Chavanas et al, 2000b; Sprecher et al, 2001).
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sequences and intron sizes. All boundaries were consistent with the
invariant AG/GT sequences that, respectively, ¯ank the beginning
and end of the majority of vertebrate exons. Intron size was found
to be relatively variable, ranging from 158 bp up to 4.8 kb. In
contrast, exons could be classi®ed into two distinct groups, one
having a relatively constant size of 128 bp 6 1 bp [except for
exons 1 (55 bp) and 31 (131 bp)] and the other having a variable
size in the range 50±97 bp [except for exon 2 (26 bp)]. As indicated
in Table IV, the constant size group corresponds to odd-
numbered exons and the variable size group corresponds to
even-numbered exons. Interestingly, sequence alignment between
SPINK5 genomic and translated sequences showed that the odd-
numbered exons encode the 15 Kazal-like domains, with the even-
numbered exons corresponding to spacer sequences. This result
suggests that odd-numbered SPINK5 exons may have arisen from
the replication of a 128 bp common ancestor.
Spectrum of mutations The entire coding sequence of the
gene, ¯anking intron boundaries, and the proximal promoter
region were ampli®ed using 35 sets of primers and screened for
mutations in 21 NS patients by DHPLC. Sequencing of samples
showing abnormal running pro®les led to the identi®cation of 18
different mutations of which 13 were novel (Table II).
Nonsense mutations Four different nonsense mutations
(R210X, R217X, R371X, and R790X) were identi®ed. They all
resulted from a C®T deamination at a CGA arginine codon,
leading to a TGA PTC. Patient 13, whose parents were
consanguineous, was homozygous for R210X in exon 8. Patient
12, and patients 1, 2, and 11, were, respectively, compound
heterozygotes for mutations R217X and R371X occurring in
exons 8 and 13. Lastly, mutation R790X in exon 25, previously
reported in another NS patient (Chavanas et al, 2000b), was present
in the heterozygous state in patients 5 and 21.
Insertions and deletions Four small deletions and four
insertions were characterized in the coding region. All of these
created a shift in the reading frame. The majority occurred within
mononucleotide repeats of 3±10 A, T, or G (153delT, 238insG,
2264insA, 2468delA, 2468insA). Other mutations included two
nucleotide deletions (377delAT, 2041delAG) and the duplication
of a G(A)4 sequence (1036insG(A)4). Mutations 153delT, 238insG,
and 2468insA were previously described in other NS patients
(Chavanas et al, 2000b).
Splice-site mutations Six different splice-site mutations were
identi®ed, four of which altered the invariant splice donor or
acceptor site consensus sequences GT (81 + 2T®A;
2240 + 1G®A) or AG (1608 ± 1G®A; 1888 ± 1G®A).
Another mutation altered the last nucleotide of exon 1 (56G®A)
whereas a further was located within intron 2 at position +5
(81 + 5G®A). The effect of mutations 2240 + 1G®A, 1888 ±
1G®A, and 81 + 5G®A on splicing was studied using RT-PCR
products from total RNA extracted from cultured keratinocytes.
Patients 6 and 7 were heterozygous for the intron 23 donor splice-
site mutation (2240 + 1G®A). RT-PCR analysis from patient 7
Table III. SPINK5 genomic primers used for mutation analysis
Ampli®ed region Forward primer (5¢®3¢) Reverse primer (5¢®3¢)
Product
size
(bp)
Annealing
temperature
(°C)
Proximal promoter region
P1 CACTGAACTCAGACACTTCAG AGCTTCCATCCTTTAGGATCC 347 62
P2 ATTCTCTGTTCAAACCTGACAC TGTGGCTATCTTCATGTTGAAG 227 62
Exons
1 CAATGCATGGAGTGGACCTGTA AGACATTTCAGGATTATACATGC 229 60
2 GTGCCCTTCTTTTATTTGCCATG AAAGCTATTAGTACCTACCAG 248 60
3 TATCTACTATGTATCAGGCATTC ATTTACCAGTTCAGAGACTAGC 371 60
4 ATCTGGGGTTCTGTGTCCAC CAGGTATGACCTAGTAATTAAG 327 58
5 TATTAGCTCAATGTAGCCTTC TGTAGGGAAAATTGTGTCATG 349 60
6 TAAAGGAGAATGACAATGCAATG TACTATTTGAAGTTAGCCTCCC 215 60
7 GCAATGTCAGAGGGACTGAG TTATCTCTCTGCTGAGTGATTC 304 58
8 TTCAGCAATTCGTAGCAGAGG TCAAAGGTTTAGGCATACAT 244 58
9 GGAAGGATCTCTGAGCCTAG GCTTCCTTTCAAAGTTATTTTTAC 371 60
10 ATCGGAAGCGTCTCTACTCA TTCATAAAATAATAACTAGAAACT 287 58
11 GAAAACAGAACTATATCTCAACT CTGTCTTGAGCCACAGTCTC 272 58
12 GCAGTGATAAAGGGACAAAA CCCAGATTGAAGAGTTAAGA 328 58
13 GAGATGTAACATTAGTTTCTGC ATGTCTCCAATCAGACAGTTTCTC 370 60
14 TGCAATTGTGAGGATTTCACAG CCTGAACATGATCTGTGGATC 304 60
15 AATCCATGCCTTCAAAGTTAATC CCAAGACTGAATGCTACACTG 392 60
16 TGAGGCAGGAGAATTGCTTG AATTGGTACTCTGGACACTTC 380 58
17 CTGATTGATGACGGAAGCTTTG CTCACGGTCTATACTCTAC 389 60
18 CAAAAGCACCTCTCAGACTAG AGTACTCTTGTATATGGGGATC 380 60
19 TTCCAAATGTGTGACCTAGTTC CAAACTCAGTGCAAAGACAGC 432 60
20 GTTTACCTTTCCACTCCAAAGC TGAACCCCTAGTTCCCTCAC 319 60
21 GAAATACAGCCACCTTCTTAAG AATACATATTATTTGCCTGGCTC 392 60
22 AGAGAAGGCCTGCAGCATAG AGCACTGCCTTTACCATAGAC 344 60
23 GTGCTGGGATTACAGGCATG TGCATGGAAGGAGCCATAGC 378 58
24 GTGCCAGAATCCTAGGAAGAC CTAGCTTGATCATGTTGACACC 332 60
25 ATTATTTTGCCTATCACAGCAAG TCATTAATTACCAGATCTGCTTC 372 60
26 TGACTGTGAGTCTTAAAGTAC GGGACAGAGTCAGCATTTCAC 252 60
27 TCTGTTTTTTTCCTGTGTTATGAGT GTGTGATGCCAAGTATCTTAGG 335 60
28 CCAACAATCAGAACTGATTAGC CAAAGTGACAAGACAAGAAAAATC 389 60
29 GGCCTCTGTTGCCAGGATG TATACAAACTTATTCAAGCAGCAG 347 60
30 TGCTGGGGTTACAGGCGTG CAAACCTCAGACCCTTCTATG 325 58
31 GTGCAAAATCAATCTTTGAGTTTG TTATATCAGTGCATTACTATG 369 60
32 GACACCTGGATGATACCTAC CCAGATAAATGTCCATTACTCAG 365 60
33 GCAGGATCTATGGATTTCTTTG ACTTTTATTGAACAGGCAGTTG 395 60
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showed, in addition to the band of normal size, a smaller band the
intensity of which was markedly reduced. Direct sequencing of the
smaller band revealed the removal of the last 59 nucleotides of exon
23 caused by activation of a cryptic splice donor site GT within
exon 23 (Fig 1a). The resulting frameshift creates a TGA stop
codon, 8 amino acids downstream of the cryptic splice-site.
Patient 10 was homozygous for the intron 20 splice acceptor site
mutation (1888 ± 1G®A). This mutation was previously shown to
lead to the deletion of guanosine 1888 through the activation of a
cryptic splice site AG, located one nucleotide downstream of the
mutation. This leads to a PTC 85 amino acids downstream of the
cryptic splice site (Fig 1b; Chavanas et al, 2000b).
Patient 7 was heterozygous for a G®A change at position +5 of
the splice donor site of intron 2 (81 + 5G®A). RT-PCR analysis
showed a larger band in addition to the band of normal size. The
intensity of both bands was reduced in comparison with the one in
the control and direct sequencing of the larger band revealed the
retention of the ®rst 103 nucleotides of intron 2 (Fig 1c). Abnormal
splicing arises from the activation of a cryptic splice donor site GT
within intron 2. This change creates a frameshift introducing a TGA
stop codon, 8 amino acids downstream of exon 2.
Patient RNA samples unavailable for study included affected
members of families 2 and 15, who were both heterozygous for
81 + 2T®A, and patients 8 and 20, who were heterozygous for
1608 ± 1G®A and 56G®A, respectively. These mutations affect
consensus or highly conserved splice-site sequences, however, and
are likely to impair splicing.
Distribution of SPINK5 mutations Cumulative data including
all SPINK5 mutations reported to date (Fig 2) con®rm that exons
2±8 are prone to mutations (Sprecher et al, 2001) and identify a
second possible mutation cluster between exons 21±26.
Consequences of mutations 81 + 5G®A, 153delT,
2240 + 1G®A, and 2459insA on SPINK5 mRNA
levels Northern blot analysis was performed with 30 mg of total
RNA extracted from the cultured keratinocytes of patient 14
(homozygous for 2459insA), patient 7 (compound heterozygote for
mutation 81 + 5G®A and 2240 + 1G®A), and patient 17
(homozygous for 153delT) using a cDNA probe speci®c for
LEKTI (Fig 3). Patient 14 showed a dramatic reduction in the
SPINK5 signal intensity compared with control levels
(quanti®cation of SPINK5/GAPDH ratios were 15% of the
control), suggesting marked nonsense-mediated SPINK5 mRNA
decay. In contrast, a signi®cant amount of SPINK5 mRNA was
observed in patients 7 and 17 (SPINK5/GAPDH ratios were 49%
and 73% of the control, respectively), indicating that these
mutations had a less severe effect on mRNA stability. To
investigate whether 153delT was associated with a secondary
splice defect that could have restored an open reading frame, we
performed RT-PCR analysis on a cDNA fragment encompassing
exons 2±4 from patient 17 keratinocytes. No additional band was
revealed in agarose gel electrophoresis. Direct sequencing of the
RT-PCR product detected no sequence variation aside from the
homozygous 153delT mutation.
Genotype analysis Of the 18 SPINK5 mutations identi®ed in
this study, seven were recurrent and were found in two (R790X,
81 + 2T®A, 238insG, 2240 + 1G®A), three (R371X,
2468delA) or ®ve (153delT) families. To investigate whether the
recurrence of these mutations resulted from independent events or
Table IV. SPINK5 intron±exon organizationa
Exon number 5¢ acceptor splice site Exon size (bp) 3¢ donor splice site Intron size (kb)
1 none (5¢ UTR) 55 ATACAAGG55gtgagcaatttgtgtg 1.241
2 tatattttcatcccagA56TGCTGCC 26 AAGATCAG81gttagtcctgcttttt 4.873
3 tttggcattatcttagG82AAATGTG 129 ATGATACT209gtgagtaaaggtttct 1.697
4 tcttgtccttttccagG210GAAAAAG 73 CAACAGAG282gtgagactatttggag >8.0
5 atcatgtcttttgcagC282TGAATTG 128 GAGAATGC410gtgagtattctctgaa »1.7
6 taacttttgattctagG411AAAACCG 64 CAGAGCAG474gtgaggtcaattgtca 0.840
7 tttccctgttcttcagG475ATGTATG 128 GAGCTGTT602gtaagtagcatcatcc 0.880
8 ttacttttcttaacagT603TTAAAAG 65 CTGAAAAG667gtaaaatgactcacca 2.725
9 aattgtcttttcaaagG668ATTTTTG 127 GAAATTTT794gtgagtatagaagtgg »1.3
10 attttactttttccagC795AAGCGGC 88 AAATTGTG882gtgagaatcagtttga »1.5
11 cttattcattattcagA883AACTCTG 128 GCCTACTT1010gtgagtatagagtttt 1.239
12 tttccctcttattcagC1011CAAGCAG 82 CATATGCA1092gtgagtggaatccatc 1.138
13 tcttctatctcggcagG1093AGCTTTG 128 GTCTTCTT1220gtgagtagccctgcag 0.773
14 aaccatccttttttagC1221CAAGCAG 82 CCTTTGAG1302gtgagtttatatatcctc 0.344
15 tgcctcaatttcacagG1303AGTTGTG 127 GCCTTCTT1429gtgagtagagcagtag 3.043
16 tttcggtttcttaaagT1430CAACAAG 50 CTGCAAAG1479gtaatattctcaggaa 2.036
17 tttcttcatttcccagG1479AAATCTG 128 AGTGTGTT1607gtgagtgtccacccca 1.588
18 tctttttctattacagC1608AAACTTG 85 CAGTTCAG1692gtagttgtttgagatc 2.930
19 ctgcttcatttggcagG1693AGCTGTG 128 GCCTTCTT1820gtgagtgggcggcagc 0.972
20 ctcccttttcttatagC1820CAGCAAG 67 CTGAAAAG1887gtagtaatcctgaatg 1.427
21 tttcttttccttttagG1888AGACATG 128 GCAGTCTT2015gtgagtgcacaaagaa 1.880
22 actttctaatttccagC2016CAGAAAG 97 ACACTCAG2112gtgagagcaacctcta 1.970
23 tcttctctgttttcagG2113ACGAATG 128 GCAAAATT2240gtaagtatttctctcaa 0.421
24 cttttttctcctccagG2241GAAAGAG 73 CAGGGAAG2313gtgagttattttttgg 0.950
25 cttcccatcttttcagG2314ATACATG 128 GAAAAACT2441gtgagtatgtttcaaa 0.158
26 attgttttccccccagG2442GAAAGGG 97 ACAAAGAG2538gtaatagatgttagac 3.441
27 ctgctactgttggtagG2539ATCTGTG 128 AGCATCTT2666gtacgtaaaaaggttt 0.804
28 ttttattattctgcagT2667GATCGAG 73 ATGCAAAG2739gttatttattaaagga 0.885
29 ctttctcattttctagG2740ATGAGTG 128 GCTGTCTT2867gtgagtaagaggattc 1.132
30 ttattttcttctctagT2868CTAACAG 97 GTTCTCTG2964gtaaggaggactattt 4.179
31 ttttttgcttcttcagG2965ATTCTGA 131 GAAAACCT3095gtaagtattcaagttg 2.407
32 ctctgatctgttttagG3096ATACGCC 91 CCCCGTCT3186gtaagtacataagtag 3.176
33 ccatcttctcttctagG3187ACGAATG ND none (3¢ UTR) ND
aFirst and last nucleotides of each exon are numbered following the cDNA sequence, with nucleotide in position 1 assigned to the ®rst nucleotide of the ATG initiation
codon in exon 1. Bases in exons are noted by underlined upper case letters and bases in introns by lower case letters. UTR, untranslated; ND, not determined.
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from a common ancient mutation, haplotype analysis was
performed using microsatellite markers (GT)17 and (CA)20
located immediately upstream of SPINK5.
Genotype analysis of families 1, 2, and 11 showed that mutation
R371X segregated with the same allele in families 1 and 2,
suggesting that patients from these families had inherited the
mutated allele from a common ancestor. This was consistent with
the common geographic origin of these families, as both originated
from England, whereas family 11 originated from Italy. Mutation
2240 + 1G®A segregated with the same allele in families 6 and 7,
who originated, respectively, from the south coast of England and
France. Mutation 153delT was associated with the same haplotype
in families 16±19 of Turkish origin, suggesting the inheritance of
the same ancestral disease allele. In family 15, of Kosovo origin, this
mutation was carried by a distinct SPINK5 allele.
In contrast, mutations 238insG, R790X, and 81 + 2T®A,
respectively, in families 9 and 12, 5 and 21, and 2 and 15 of various
geographic origins, segregated with different alleles within each pair
of families. Finally, haplotype analysis of families 3, 4, and 8, who
share the mutation 2468delA, showed that family 3 (Northern
Ireland) and family 8 (France) had a common SPINK5 haplotype.
We could not determine which one of the alleles in patient 3 was
carrying the mutation, however, as we did not have access to his
parents' DNA.
Six other mutations identi®ed in this study (81 6 2T®A,
238insG, 1888±1G®A, 2264insA, R790X, and 2468insA) were
previously identi®ed in unrelated NS patients from various
geographic origins (Chavanas et al, 2000b; Sprecher et al, 2001).
Two of these mutations (R790X and 2468insA) occurred in two
Japanese and four Pakistani families, respectively. Haplotype
analysis showed that mutation R790X was associated with the
same haplotype at the SPINK5 locus in the two Japanese families,
and that mutation 2468insA was carried by a unique mutated allele
in the four Pakistani families that were studied (unpublished data).
Mutations 238insG and 1888±1G®A, respectively, were observed
in six and three unrelated families of different genetic backgrounds.
These mutations showed no evidence for a founder effect in the
families studied and may be true mutational hotspots. Haplotype
analysis for mutations 81 6 2T®A and 2264insA, identi®ed in
four and three families, respectively, could not be performed.
SPINK5 polymorphisms A total of 45 intragenic nucleotide
changes located within 650 bp of exon boundaries was identi®ed
in patients and in controls during the study (Table V). These
changes were identi®ed in patients carrying two causative
mutations leading to PTCs, and thus were considered as
nonpathogenic sequence variants. They were almost equally
distributed between the coding region (56%) and intronic
sequences (44%). More than half of those occurring within the
Figure 1. Schematic representation of the effects of splicing
mutations identi®ed in patients 6, 7, and 10. Exons present in the
mRNA are denoted by black boxes; exons or parts of exons absent are
denoted by hatched boxes. Gray boxes denote novel sequences. Upper
case letters denote bases in exons, whereas lower case letters denote bases
in introns. The broken V-shaped lines designate regions of pre-mRNA
that are removed by normal splicing (N) or by abnormal splicing in the
patient. Cryptic splice sites used for aberrant splicing are underlined.
``Stop'' denotes a PTC.
Figure 2. Localization and nature of SPINK5 mutations. Top:
schematic genomic organization of SPINK5. The gene comprises 33
exons (numbered boxes) and spans a region of 61 kb. Exons 1 and 33,
respectively, contain the initiation (ATG) and stop (TGA) codons of
translation. Bottom: schematic representation of the predicted LEKTI
protein. The polypeptide contains 1064 amino acids. It is composed of
an N-terminal secretory peptide signal (SPS) sequence and 15 domains
(plain, dotted, or striped cylinders) separated by linker regions (gray boxes).
Typical Kazal-type domains are depicted by striped boxes and Kazal-like
domains by plain boxes. Dotted boxes correspond to Kazal-like domains
found as proteolytic fragments in the serum (MaÈgert et al, 1999).
SPINK5 mutations identi®ed in this study are indicated by black
symbols. Mutations previously reported (Chavanas et al, 2000b; Sprecher
et al, 2001) appear in white along the protein.
358 BITOUN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
coding region (56%) generated changes in the amino acid sequence.
Of these changes, E420K was found in 26.2% of the patients
studied.
DISCUSSION
In this study, we report the characterization of 13 novel SPINK5
mutations among a total of 18 different defects identi®ed in 21 NS
patients. SPINK5 mutations in both alleles were identi®ed in 16
patients, whereas only one heterozygous mutation could be
identi®ed in ®ve patients (patients 3, 4, 6, 9, and 20) after the
screening of the entire coding region of SPINK5, ¯anking splice
sites, and the proximal region of the promoter. It is thus possible
that the missing mutations in these patients lie in the distal region of
the promoter, in intronic sequences, or in the 3¢ untranslated
region of the gene. With the exception of three splice-site
mutations whose consequences could not be assessed, all mutations
lead to PTCs of translation.
Predicted effects of SPINK5 mutations The observation that
the majority if not all SPINK5 mutations lead to PTCs suggests that
a signi®cant proportion of these mutations result in null or very low
expression of the mutant SPINK5 alleles as a consequence of
nonsense-mediated mRNA decay (Culbertson, 1999; Frischmeyer
and Dietz, 1999). Loss of function is consistent with the recessive
mode of NS inheritance and is supported by northern blot analysis
of cultured epidermal keratinocytes from ®ve NS patients. These
patients include patient 14 reported here, together with four
patients (9, 11, 12, and 13) reported in Chavanas et al (2000b),
which are all homozygous for PTCs in exons 24 and 26 (note: in
Fig 1(a) of Chavanas et al (2000b) the patient panel should read
``control, 8, 9, 11, 12, and 13'' and not ``control, patients 2, 3, 6, 7
Table V. SPINK5 polymorphismsa
Polymorphism Nucleotide change Location Veri®cation method Frequency (21 patients)b
Amino acid changes (n = 14)
N39S AAT®AGT Exon 3 sequencing 2.4%
D106N GAT®AAT Exon 5 sequencing 4.8%
V335A GTC®GCC Exon 11 +AccI 7.1%
N368S AAT®AGT Exon 13 sequencing 16.7%
D386N GAT®AAT Exon 13 ±Sau3A I 7.1%
E420K GAA®AAA Exon 14 ±Hinf I 26.2%
R425S AGA®AGT Exon 14 sequencing 2.4%
G519E GGA®GAA Exon 17 ±Sau96I 4.8%
R620K AGA®AAA Exon 20 sequencing 2.4%
M781I ATG®ATA Exon 25 sequencing 2.4%
K822R AAA®AGA Exon 26 sequencing 2.4%
E825D GAG®GAT Exon 26 sequencing 7.1%
C929R TGC®CGC Exon 29 +FokI 2.4%
H972R CAT®CGT Exon 30 +Nla III 4.8%
Silent changes (n = 11)
R371R CGA®CGG Exon 13 ±TaqI 7.1%
H396H CAC®CAT Exon 13 ±NlaIII 19%
G463G GGG®GGA Exon 15 sequencing 9.5%
G519G GGA®GGG Exon 17 sequencing 21.4%
V553V GTT®GTC Exon 18 +Taq I 28.6%
A617A GCT®GTT Exon 20 sequencing 4.8%
L786L CTT®CTC Exon 25 sequencing 7.1%
G804G GGT®GGC Exon 25 sequencing 23.8%
K823K AAG®AAA Exon 26 sequencing 2.4%
K824K AAA®AAG Exon 26 sequencing 2.4%
G1003G GGC®GGT Exon 31 sequencing 11.9%
Intronic nucleotide changes (n = 20)
82±31 A®G Intron 2 ±AluI 54.8%
283±12 T®A Intron 5 +NlaIII 2.4%
475±39 A®G Intron 6 sequencing 4.8%
1011±12 C®T Intron 11 sequencing 28.6%
1093±10 A®G Intron 12 +BsmA I 54.8%
1302+19 G®A Intron 14 +MmeI 11.9%
1607+47 C®T Intron 17 +HaeIII 7.1%
1607+49delC G(C)4T®G(C)3T Intron 17 sequencing 4.8%
1821±47 T®C Intron 19 ±MaeII 2.4%
1888±14 T®C Intron 20 sequencing 16.7%
2241±27 T®C Intron 23 sequencing 33.4%
2313+21 C®G Intron 24 sequencing 2.4%
2313+31 G®C Intron 24 +MnlI 35.7%
2313+48 A®G Intron 24 +HincII 59.7%
2539±7 T®G Intron 26 ±ApaLI 2.4%
2667±22insT (T)9AA®(T)10AA Intron 27 sequencing 2.4%
2965±9 C®T Intron 30 sequencing 2.4%
2965±46 T®C Intron 30 +MaeIII 28.6%
3217+23 T®C Intron 33 ±BsrI 9.5%
3217+23 T®G Intron 33 +EcoRII 2.4%
aAll changes have been detected by DHPLC analysis and identi®ed by sequencing. Nucleotides involved in changes are underlined. Only intronic changes located at a
distance <50 bp of the nearest exon are indicated.
bFrequencies have been calculated as follows: number of patients' alleles carrying the nucleotide change 3100/total number of screened alleles.
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and 8''). These individuals show a dramatic (85%±91%) reduction
in expression of SPINK5 mRNA in comparison with the control.
Three other patients, one homozygote for a splice-site mutation
leading to a PTC in exon 21 (patient 8 in Chavanas et al, 2000b),
one compound heterozygote for mutations leading to PTCs in
intron 2 and exon 24 (patient 7, this study), and one homozygous
for a PTC in exon 3 (patient 17, this study), displayed a signi®cant
amount of SPINK5 mRNA (34%, 49%, and 73% of the control,
respectively) (Fig 2). This observation suggests that different PTC
mutations in SPINK5 have variable effects on mRNA stability. The
importance of the PTC position on mRNA stability remains to be
investigated. This ®nding raises the possibility that SPINK5
mutations associated with signi®cant mutant transcript levels may
lead to the synthesis of truncated, structurally abnormal, and
nonfunctional LEKTI polypeptide. The detection of LEKTI levels
and/or activity in patient skin biopsies and/or cultured
keratinocytes will thus constitute, in the future, major progress in
the understanding of the effects of SPINK5 mutations on the
expression of the mutant polypeptide.
Recurrence of SPINK5 mutations Thirty-nine percent of the
mutations (seven out of 18) identi®ed in this study were found to
be recurrent. When these results are combined with the recent
study by Sprecher et al it appears that, of the 36 SPINK5 mutations
reported to date, 13 (36%) are recurrent. Five of these mutations
(R371X, 2240 6 1G®A, 153delT, R790X, and 2468insA) are
likely to result from founder effects, whereas four other mutations
(81 6 2T®A, 238insG, 1888±1G®A, and 2264insA) may be
mutational hotspots. These results enable a more informed and
strategic approach to mutation detection.
Genotype±phenotype correlations The association of
neonatal erythroderma, TI, and atopic manifestations was present
in the majority of patients whose clinical course could be followed
after the neonatal period, thus con®rming the diagnostic value of
these parameters. Only two out of 23 patients (patients 13.1 and
15.2, aged 8 and 6 y) did not have erythroderma at birth or TI,
respectively. In contrast, ichthyosis linearis circum¯exa developed
in 12 patients only. Of the associated features, failure to thrive and
hypernatraemic dehydration were life-threatening complications
that occurred in early childhood in 18 and 12 patients, respectively.
Our study shows variation in clinical severity between and
within families, with no clear genotype±phenotype correlation.
Intrafamilial variation in disease severity was found in four of the
®ve multiplex families studied (12, 13, 19, and 21) (Table I). This
result suggests that differences in genetic background and in
environmental factors may also in¯uence the disease phenotype.
Homozygosity for 153delT in exon 3 was lethal within the ®rst
10 d of life in three patients (17, 18, and 19.1) and was associated
with a severe phenotype during the neonatal period in two patients
(16 and 19.2), all of Turkish origin (Table I). This severe outcome
is unlikely to be due to variation in the access to, or quality of,
health care as these patients were treated in specialized hospital units
in France. A lethal form of autosomal recessive congenital
erythroderma was previously reported in four consanguineous
families, two of which originated from Turkey (Shield et al, 1992).
These patients died within the ®rst months of life despite intensive
medical treatment in hospitals in London. There was no evidence
for immunode®ciency, and it was suggested that this disease could
be a distinct entity in the spectrum of infantile erythroderma. In the
light of our results, it is possible that these patients were affected
with severe NS, and that the Turkish patients reported in this study
were homozygous for 153delT.
LEKTI is the ®rst serine protease inhibitor to be involved in a
human disease with allergic manifestations. Recently, mutations in
the Kazal-type 1 pancreatic trypsin inhibitor have been identi®ed in
chronic pancreatitis (Witt et al, 2000). Together with the
description in periodontal disease with palmoplantar keratosis
(Papillon±Lefevre syndrome) (Toomes et al, 1999) of mutations in
cathepsin C, a potent activator of granule serine proteases from
leukocytes, these results provide further evidence for the implica-
tion of serine proteases inhibitors and their activators in human
genetic diseases.
ELECTRONIC DATABASE INFORMATION
Accession numbers and URLs for data in this article are as follows:
National Center for Biotechnology Information (NCBI), http://
www.ncbi.nlm.nih.gov/(for GenBank accession nos. for SPINK5:
AJ27094, AJ391230-54, AJ276577-80, and AC008722 for BAC
clone 94F21)
GenBank Overview, http://www.ncbi.nlm.nih.gov/GenBank/
GenBank Overview.html (for LEKTI cDNA sequence [accession
number AJ228139])
Online Mendelian Inheritance in Man (OMIM), http://
www.ncbi.nlm.nih.gov/Omim (for Netherton syndrome
[MIM256500])
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